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Fixed drug eruption is a manifestation of T-cell mediated drug hypersensitivity. We report, clinically
conﬁrm and highlight the occurrence of a ﬁxed drug eruption with cross-reactivity between structurally
related, though distinctly classiﬁed, antibiotics frequently used in the treatment of cystic ﬁbrosis.
 2009 Elsevier Ltd. All rights reserved.1. Letter
A 30-year-old man with cystic ﬁbrosis developed painful,
circular, oedematous, dusky red to violaceous dermal plaques over
his back, ﬁnger webs, dorsal feet, thighs and volar aspect of wrist
(Fig. 1A). This had been occurring in a progressively painful but
erratic manner over 3 years. The lesions occurred in ﬁxed positions
within 1 h of receiving intravenous antibiotics for infective exac-
erbations of cystic ﬁbrosis. Fixed drug eruption (FDE) was diag-
nosed. He had receivedmultiple intravenous and oral combinations
of penicillin (amoxicillin and ﬂucloxacillin), cephalosporin (cefta-
zidime), monobactam (aztreonam), carbapenem (meropenem),
aminoglycoside (tobramycin, gentamicin), polymyxin (colomycin),
sulphonamide (septrin) and macrolide (erythromycin and clary-
thromycin) antibiotics as well as regular nebulised colomycin and
tobramycin. Careful course by course evaluation suggested mer-
epenem, gentamicin, aztreonam and ceftazidime to be the most
likely causative agents.
Investigation with epicutaneous patch testing (0–30% drug
mixed in Vaseline within aluminium chamber applied to non-
affected skin and eruption sites), and in-vitro lymphocytepharmacology Unit, South-
ad, Southampton, SO16 6YD,
.
rved.transformation testing (isolated monocyte and lymphocyte
cultures with increasing concentrations of suspected drug in-vitro)
were non-diagnostic and drug provocation testing was performed.
This demonstrated rapid reactivation of painful ﬁxed plaques to
aztreonam and ceftazidime within 30 min (Fig. 1B,C). Meropenem
and gentamicin were without reaction and subsequently used at
full clinical doses.
FDE was ﬁrst described by Brocq in 1894.1 It is characterised by
the rapid onset of single or multiple circular erythematous to
violaceous oedematous plaques on the skin though morphological
variants have been described. These lesions maybe asymptomatic
or painful, classically itching or burning. The pathognomic feature
is the reappearance of the lesions at identical sites on re-exposure
to the causative agent. Residual hyperpigmentation from lichenoid
epidermal basal layer degeneration is characteristic. Histology of
active lesions demonstrates marked oedema and a mixed peri-
vascular inﬁltrate in the upper papillary.2
Immunological studies demonstrate a stable population of
effector CD8þ lymphocytes in resting lesions that are activated on
administration of the causative drug resulting in localised damage.
Viral infection has been suggested in the evolution of effector
T-cells.3 Familial clusters may hint at a genetic susceptibility.4
Conﬁrmation of FDE by epicutaneous patch testing has been
reported for certain drugs, whereas the in-vitro lymphocyte
transformation test is unhelpful as drug speciﬁc lymphocytes are
only found in the skin, not the peripheral circulation5,6 Systemic
provocation remains the gold standard.4
Fig. 1. Cutaneous eruption seen subsequent to; A – clinically administered course of ceftazidime, gentamicin and ﬂucloxacillin. B – administration of ceftazidime alone.
C – administration of aztreonam alone.
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b-Lactam core structure characteristic of penicillins, cephalosporins
and carbapenems but does share a common R-group side chain
with ceftazidime. This means it has potential for cross-reactivity
with ceftazidime but very little with penicillins, carbapenems or
other cephalosporins.7
Antibiotic hypersensitivity is more prevalent in patients with
cystic ﬁbrosis, occurring in approximately one third, often to
multiple drugs and correlates to cumulative drug exposure.8 It is
a clinically signiﬁcant problem as these patients rely on prolonged
and repeated courses of antibiotics to treat their chronic pulmonary
sepsis and hypersensitivity reduces therapeutic choice. Clinical
studies in cystic ﬁbrosis patients support in-vitro studies with low
levels of hypersensitivity to aztreonam even in penicillin-allergic
patients.9,10
Although aztreonam–ceftazidime IgE mediated cross-reactivity
is well known, to our knowledge, this is the ﬁrst report of FDE to
aztreonam–ceftazidime.
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